- Total income
- ₹5,727 Cr
- Profit
- ₹699 Cr

Gland Pharma
About Gland Pharma
Gland Pharma is a publicly listed company based in Hyderabad (India) founded in 1978 by Ravi Penmetsa and Pvn Raju, and was acquired by Fosun in July 2016. Generic injectable drugs are manufactured across therapeutic segments. The company has 4,332 employees. Gland Pharma has completed 1 acquisition, including Cenexi. Gland Pharma was last valued at $445.93 million in November 2013. Its chief executive, as recorded, is Srinivas Sadu. Its Indian entity Gland Pharma Ltd reported revenue of βΉ6,747 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.
Company details
The company was founded in 1978 in Hyderabad, India, and operates in the pharmaceutical sector as a manufacturer of generic injectable drugs. A portfolio of products has been established in sterile injectables, oncology, and ophthalmics, with emphasis on complex injectables and various delivery systems. Diverse injectable needs are addressed through a stable supply chain, serving global markets from its base in India.
Gland Pharma is ranked #414 on the Fortune India 500 (2025) and #135 on the Fortune MNC 500 India (2026).
Recognitions & Rankings of Gland Pharma
- Total income
- ₹5,727 Cr
- Profit
- ₹699 Cr
- Headquarters Hyderabad, India
- Employees 4,332
- Founders Ravi Penmetsa, Pvn Raju
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website glandpharma.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Fosun (Jul 2016)
- Legal Name Gland Pharma Ltd.
- Market Cap₹55,871 Cr
GLAND · NSE
- Share Price₹3,348.00
-1.12% today
- Revenue₹6,431 Cr
FY 2025-26 · +14.5% YoY
- EBITDA₹1,605 Cr
Margin 25.0%
- Net Profit₹1,042 Cr
FY 2025-26 · +49.5% YoY
- P/E (TTM)43.9x
P/B 5.2x
- ROE10.5%
ROCE 14.6%
- Debt / Equity0.03
Interest cover 2.8x
- Latest Funding Round$208.59M (USD), Unspecified
Nov 2013
- InvestorsKKR
& 2 more
- Employee Count4,332
- Investments & Acquisitions
- Acquired byFosun
(Jul 2016)
Associated legal entities of Gland Pharma
Gland Pharma operates through Gland Pharma Ltd, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gland Pharma Ltd Listed CIN L24239TG1978PLC002276 | Active | 20 Mar 1978 | Hyderabad, Telangana | ₹6,747 Cr | 4,769 | 10 | View details |
Apps and channels of Gland Pharma
its YouTube channel Gland Pharma has 184 subscribers and 7 videos.
Videos from Gland Pharma
The most watched videos on Gland Pharma's YouTube channel, Gland Pharma (184 subscribers). Click a video to play it here.
More on Gland Pharma.
Funding Insights of Gland Pharma
- Total Rounds 1
- Last Round Unspecified β $208.59M
- First Round $208.59M
(Nov 2013)
- Investors Count 2
All 1 funding rounds of Gland Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2013 | $208.59M | Unspecified | $445.93M | KKR |
| Date | Valuation | Stage |
|---|---|---|
| Nov 2013 | $445.93M | β’β’β’β’β’β’β’β’ |
Last known valuation $445.93M (Nov 2013). 3 investors in total: 3 institutional.
Investors in Gland Pharma
Gland Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, Fosun and Gland Celsus Bio Chemicals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Provider of legal, accounting, book keeping, and tax consulting services | 2007 | glandcelsus.com | Hyderabad, India | |
Diversified investment, asset management, and insurance services are offered globally. | 1992 | fosun.com | Shanghai, China |
Investor details for Gland Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Gland Pharma Ltd (Gland Pharma)
Gland Pharma Ltd is the primary company behind Gland Pharma. The board of Gland Pharma Ltd currently have 8 directors; the longest-serving is Udo Jahannes Vetter, appointed in 2018. 27 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Udo Jahannes Vetter DIN 00707474 | Director | 07 Feb 2018 | 8 yrs 9 mo | Gland Pharma Ltd |
| Srinivas Sadu DIN 06900659 | Whole-time director | 25 Apr 2019 | 7 yrs 6 mo | Gland Pharma Ltd |
| Essaji Goolam Vahanvati DIN 00157299 | Director | 30 Sep 2020 | 6 yrs 1 mo | Gland Pharma Ltd |
| Jia Ai Zhang DIN 09170927 | Director | 17 May 2021 | 5 yrs 6 mo | Gland Pharma Ltd |
| Naina Lal Kidwai DIN 00017806 | Director | 17 May 2021 | 5 yrs 6 mo | Gland Pharma Ltd |
| Wei Huang DIN 10818586 | Director | 04 Nov 2024 | 2 yrs | Gland Pharma Ltd |
| William Robert Keller DIN 11593622 | Director | 15 Jun 2026 | 5 mo | Gland Pharma Ltd |
| Xingli Wang DIN 11899926 | Additional Director | 01 Oct 2026 | 1 mo | Gland Pharma Ltd |
People of Gland Pharma
5 people are tracked at Gland Pharma (4 in leadership, 1 in team); the tracked headcount is 4,332.
| Name | Role | Group |
|---|---|---|
Ravi Penmetsa | Co-Founder | Leadership |
Pvn Raju | Co-Founder | Leadership |
| CEO & Managing Director | Leadership | |
Shyamakant Giri | CEO | Leadership |
Raghava Bomminayuni | Senior Executive | Team |
Complete people profiles for Gland Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Gland Pharma
Gland Pharma is a publicly listed company on the NSE with ticker symbol GLAND in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Nov 2020
- Listed onBSE: 543245 · NSE: GLAND
- Listed entityGland Pharma Ltd.
- Exchange sectorHealth technology
- ISININE068V01023
- Share price₹3,052.30 (-1.26% on the day) · 2026-10-14
- Market capitalisation₹50,959 Cr
- Price to earnings44.6
- EPS (diluted, trailing year)₹68.47
- Dividend yield0.65%
- Volume (last session)178,927
Financials of Gland Pharma
Exchange-reported figures of Gland Pharma Ltd, the listed company behind Gland Pharma (NSE: GLAND).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 6,431 | 5,616 | 5,665 | 3,625 | 4,401 | 3,463 | 2,633 |
| Revenue growth | +14.5% | -0.9% | +56.3% | -17.6% | +27.1% | +31.5% | - |
| EBITDA | 1,605 | 1,269 | 1,333 | 968 | 1,510 | 1,302 | 955 |
| EBITDA margin | +25.0% | +22.6% | +23.5% | +26.7% | +34.3% | +37.6% | +36.3% |
| Profit before tax | 1,465 | 1,063 | 1,133 | 1,055 | 1,619 | 1,335 | 993 |
| Net profit | 1,042 | 697 | 772 | 821 | 1,208 | 997 | 760 |
| Net profit margin | +16.2% | +12.4% | +13.6% | +22.6% | +27.5% | +28.8% | +28.9% |
| EPS (βΉ) | 62.35 | 42.40 | 46.90 | 47.42 | 73.75 | 60.94 | 49.88 |
| Balance sheet | |||||||
| Total assets | 10,878 | 9,652 | 9,274 | 7,965 | 7,164 | 5,910 | 3,654 |
| Net worth | 10,358 | 9,151 | 8,724 | 7,959 | 7,158 | 5,903 | 3,646 |
| Total debt | 284 | 314 | 372 | 4.45 | 4.74 | 5.00 | 4.96 |
| Cash & bank | 3,359 | 2,556 | 1,839 | 3,771 | 3,093 | 3,006 | 1,325 |
| Net working capital | 6,109 | 5,425 | 4,478 | 6,172 | 5,115 | 4,611 | 2,488 |
| Cash flow | |||||||
| Cash from operations | 1,031 | 915 | 997 | 364 | 791 | 605 | 701 |
| Cash from investing | 188 | 1,718 | (1,749) | 1,211 | (999) | (1,520) | (761) |
| Cash from financing | (417) | (433) | (799) | 14.92 | 34.90 | 1,238 | (6.87) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,834 | 1,800 | 1,743 | 1,695 | 1,487 | 1,506 | 1,425 | 1,384 |
| Revenue growth (YoY) | +23.3% | +19.6% | +22.3% | +22.5% | +5.8% | +7.4% | - | - |
| Other income | 69.05 | 61.23 | 111 | 63.17 | 84.16 | 57.53 | 44.03 | 58.49 |
| EBITDA | 484 | 489 | 513 | 411 | 314 | 368 | 348 | 360 |
| EBITDA margin | +26.4% | +27.2% | +29.4% | +24.2% | +21.1% | +24.4% | +24.4% | +26.0% |
| Depreciation | 115 | 111 | 109 | 108 | 106 | 101 | 95.76 | 96.33 |
| Interest | 7.14 | 4.36 | 10.03 | 3.93 | 7.82 | 11.50 | 7.45 | 22.82 |
| Profit before tax | 431 | 435 | 506 | 362 | 284 | 313 | 288 | 299 |
| Tax | 140 | 118 | 139 | 101 | 100 | 97.26 | 102 | 94.61 |
| Net profit | 291 | 317 | 367 | 261 | 184 | 215 | 187 | 205 |
| EPS (βΉ) | 17.62 | 19.22 | 22.23 | 15.87 | 11.15 | 13.08 | 11.32 | 12.42 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 4,552 | 4,116 | 4,167 | 3,617 | 4,401 | 3,463 | 2,633 |
| Revenue growth | +10.6% | -1.2% | +15.2% | -17.8% | +27.1% | +31.5% | - |
| EBITDA | 1,639 | 1,443 | 1,409 | 962 | 1,511 | 1,302 | 955 |
| EBITDA margin | +36.0% | +35.1% | +33.8% | +26.6% | +34.3% | +37.6% | +36.3% |
| Profit before tax | 1,748 | 1,466 | 1,405 | 1,048 | 1,619 | 1,335 | 993 |
| Net profit | 1,315 | 1,088 | 1,044 | 815 | 1,209 | 997 | 760 |
| Net profit margin | +28.9% | +26.4% | +25.0% | +22.6% | +27.5% | +28.8% | +28.9% |
| EPS (βΉ) | 78.88 | 66.14 | 63.34 | 47.11 | 73.78 | 60.95 | 49.88 |
| Balance sheet | |||||||
| Total assets | 10,860 | 9,783 | 9,020 | 7,959 | 7,165 | 5,910 | 3,654 |
| Net worth | 10,810 | 9,755 | 8,995 | 7,953 | 7,158 | 5,903 | 3,646 |
| Total debt | 2.75 | 5.23 | 3.66 | 4.45 | 4.74 | 5.00 | 4.96 |
| Cash & bank | 3,178 | 2,433 | 1,599 | 3,767 | 3,086 | 3,005 | 1,325 |
| Net working capital | 5,789 | 5,245 | 4,158 | 6,159 | 5,108 | 4,611 | 2,488 |
| Cash flow | |||||||
| Cash from operations | 1,135 | 1,074 | 1,136 | 368 | 791 | 605 | 701 |
| Cash from investing | (74.03) | 1,582 | (2,918) | 1,211 | (1,007) | (1,521) | (761) |
| Cash from financing | (316) | (340) | (7.40) | 14.92 | 34.90 | 1,238 | (6.87) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,402 | 1,287 | 1,262 | 1,178 | 1,074 | 1,039 | 1,030 | 1,011 |
| Revenue growth (YoY) | +30.5% | +23.9% | +22.4% | +16.5% | +1.1% | +2.7% | - | - |
| Other income | 71.38 | 58.82 | 106 | 60.21 | 82.59 | 54.74 | 43.72 | 65.06 |
| Total expenses | 854 | 813 | 754 | 780 | 699 | 680 | 636 | 620 |
| EBITDA | 548 | 474 | 508 | 397 | 375 | 359 | 394 | 391 |
| EBITDA margin | +39.1% | +36.8% | +40.2% | +33.7% | +34.9% | +34.5% | +38.3% | +38.7% |
| Depreciation | 45.15 | 43.95 | 43.11 | 44.53 | 44.84 | 43.77 | 43.07 | 43.77 |
| Interest | 3.15 | 0.69 | 6.17 | 0.50 | 3.97 | 7.44 | 3.45 | 18.31 |
| Profit before tax | 571 | 488 | 565 | 412 | 409 | 362 | 391 | 394 |
| Tax | 146 | 123 | 144 | 105 | 107 | 93.12 | 101 | 99.01 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,834 | 1,800 | 1,743 | 1,695 | 1,487 | 1,506 | 1,425 | 1,384 |
| Revenue growth (YoY) | +23.3% | +19.6% | +22.3% | +22.5% | +5.8% | +7.4% | - | - |
| Other income | 69.05 | 61.23 | 111 | 63.17 | 84.16 | 57.53 | 44.03 | 58.49 |
| EBITDA | 484 | 489 | 513 | 411 | 314 | 368 | 348 | 360 |
| EBITDA margin | +26.4% | +27.2% | +29.4% | +24.2% | +21.1% | +24.4% | +24.4% | +26.0% |
| Depreciation | 115 | 111 | 109 | 108 | 106 | 101 | 95.76 | 96.33 |
| Interest | 7.14 | 4.36 | 10.03 | 3.93 | 7.82 | 11.50 | 7.45 | 22.82 |
| Profit before tax | 431 | 435 | 506 | 362 | 284 | 313 | 288 | 299 |
| Tax | 140 | 118 | 139 | 101 | 100 | 97.26 | 102 | 94.61 |
| Net profit | 291 | 317 | 367 | 261 | 184 | 215 | 187 | 205 |
| EPS (βΉ) | 17.62 | 19.22 | 22.23 | 15.87 | 11.15 | 13.08 | 11.32 | 12.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 6,431 | 5,616 | 5,665 | 3,625 | 4,401 | 3,463 | 2,633 |
| Revenue growth | +14.5% | -0.9% | +56.3% | -17.6% | +27.1% | +31.5% | - |
| Other income | 316 | 214 | 170 | 240 | 224 | 135 | 139 |
| Total expenses | 4,825 | 4,348 | 4,332 | 2,656 | 2,891 | 2,161 | 1,678 |
| Employee cost | 1,629 | 1,402 | 1,257 | 403 | 339 | 311 | 278 |
| EBITDA | 1,605 | 1,269 | 1,333 | 968 | 1,510 | 1,302 | 955 |
| EBITDA margin | +25.0% | +22.6% | +23.5% | +26.7% | +34.3% | +37.6% | +36.3% |
| Depreciation | 424 | 378 | 345 | 147 | 110 | 98.78 | 94.59 |
| Interest | 33.28 | 42.00 | 26.20 | 7.45 | 5.24 | 3.41 | 7.18 |
| Profit before tax | 1,465 | 1,063 | 1,133 | 1,055 | 1,619 | 1,335 | 993 |
| Tax | 437 | 364 | 360 | 274 | 407 | 338 | 220 |
| Net profit | 1,042 | 697 | 772 | 821 | 1,208 | 997 | 760 |
| Net profit margin | +16.2% | +12.4% | +13.6% | +22.6% | +27.5% | +28.8% | +28.9% |
| EPS (βΉ) | 62.35 | 42.40 | 46.90 | 47.42 | 73.75 | 60.94 | 49.88 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.48 | 16.48 | 16.47 | 16.47 | 16.43 | 16.36 | 15.50 |
| Reserves & surplus | 10,341 | 9,134 | 8,707 | 7,942 | 7,141 | 5,887 | 3,631 |
| Shareholders' funds (net worth) | 10,358 | 9,151 | 8,724 | 7,959 | 7,158 | 5,903 | 3,646 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 284 | 314 | 372 | 4.45 | 4.74 | 5.00 | 4.96 |
| Total debt | 284 | 314 | 372 | 4.45 | 4.74 | 5.00 | 4.96 |
| Total liabilities | 10,878 | 9,652 | 9,274 | 7,965 | 7,164 | 5,910 | 3,654 |
| Assets | |||||||
| Gross block | 6,785 | 5,613 | 5,012 | 2,295 | 2,081 | 1,431 | 1,348 |
| Net block | 4,492 | 4,147 | 3,947 | 1,571 | 1,502 | 954 | 968 |
| Capital work in progress | 342 | 151 | 238 | 177 | 191 | 338 | 188 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 155 | 0.00 | 0.00 |
| Inventories | 1,744 | 1,685 | 1,655 | 1,945 | 1,186 | 1,275 | 756 |
| Sundry debtors | 1,891 | 1,517 | 1,559 | 871 | 1,199 | 671 | 602 |
| Cash & bank balances | 3,359 | 2,556 | 1,839 | 3,771 | 3,093 | 3,006 | 1,325 |
| Loans & advances | 532 | 1,025 | 592 | 313 | 219 | 172 | 163 |
| Total current assets | 7,527 | 6,783 | 5,645 | 6,901 | 5,697 | 5,124 | 2,846 |
| Total current liabilities | 1,418 | 1,358 | 1,167 | 728 | 582 | 512 | 358 |
| Net working capital | 6,109 | 5,425 | 4,478 | 6,172 | 5,115 | 4,611 | 2,488 |
| Total assets | 10,878 | 9,652 | 9,274 | 7,965 | 7,164 | 5,910 | 3,654 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2,556 | 357 | 1,909 | 319 | 492 | 170 | 236 |
| Net cash from operating activities | 1,031 | 915 | 997 | 364 | 791 | 605 | 701 |
| Net cash from investing activities | 188 | 1,718 | (1,749) | 1,211 | (999) | (1,520) | (761) |
| Net cash from financing activities | (417) | (433) | (799) | 14.92 | 34.90 | 1,238 | (6.87) |
| Net change in cash | 803 | 2,199 | (1,552) | 1,590 | (174) | 323 | (66.91) |
| Closing cash | 3,359 | 2,556 | 1,839 | 3,771 | 3,093 | 3,006 | 1,325 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.5% | -0.9% | +56.3% | -17.6% | +27.1% | +31.5% | - |
| EBITDA growth | +26.5% | -4.8% | +37.7% | -35.9% | +16.0% | +36.3% | - |
| PBT growth | +37.8% | -6.2% | +7.4% | -34.8% | +21.3% | +34.4% | +9997.0% |
| Net income growth | +49.5% | -9.7% | -5.9% | -32.1% | +21.2% | +31.2% | - |
| Revenue CAGR (3Y) | +21.1% | +8.5% | +17.8% | +11.2% | - | - | - |
| EBITDA CAGR (3Y) | +18.4% | -5.6% | +0.8% | +0.5% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +16.0% | +12.4% | +13.6% | +21.6% | +27.5% | +28.8% | +29.4% |
| Return on capital employed | +14.6% | +11.7% | +13.4% | +14.0% | +24.8% | +28.0% | +27.4% |
| Return on net worth | +10.5% | +7.8% | +9.3% | +10.3% | +18.6% | +20.9% | +21.2% |
| Debt / equity | 0.03 | 0.04 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 2.82 | 4.71 | 2.65 | 0.91 | 0.37 | 0.28 | 0.83 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.04 | 1.06 | 1.55 | 1.66 | 2.51 | 2.49 | 1.95 |
| Inventory turnover | 3.75 | 3.36 | 3.15 | 2.32 | 3.58 | 3.41 | 3.48 |
| Debtors turnover | 3.77 | 3.65 | 4.66 | 3.72 | 4.71 | 5.44 | 4.38 |
| EPS (βΉ) | 62.35 | 42.40 | 46.90 | 47.42 | 73.75 | 60.94 | 49.88 |
| Dividend per share (βΉ) | 20.00 | 18.00 | 20.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 628.67 | 555.40 | 529.65 | 483.23 | 435.64 | 360.86 | 235.32 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,402 | 1,287 | 1,262 | 1,178 | 1,074 | 1,039 | 1,030 | 1,011 |
| Revenue growth (YoY) | +30.5% | +23.9% | +22.4% | +16.5% | +1.1% | +2.7% | - | - |
| Other income | 71.38 | 58.82 | 106 | 60.21 | 82.59 | 54.74 | 43.72 | 65.06 |
| Total expenses | 854 | 813 | 754 | 780 | 699 | 680 | 636 | 620 |
| EBITDA | 548 | 474 | 508 | 397 | 375 | 359 | 394 | 391 |
| EBITDA margin | +39.1% | +36.8% | +40.2% | +33.7% | +34.9% | +34.5% | +38.3% | +38.7% |
| Depreciation | 45.15 | 43.95 | 43.11 | 44.53 | 44.84 | 43.77 | 43.07 | 43.77 |
| Interest | 3.15 | 0.69 | 6.17 | 0.50 | 3.97 | 7.44 | 3.45 | 18.31 |
| Profit before tax | 571 | 488 | 565 | 412 | 409 | 362 | 391 | 394 |
| Tax | 146 | 123 | 144 | 105 | 107 | 93.12 | 101 | 99.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 4,552 | 4,116 | 4,167 | 3,617 | 4,401 | 3,463 | 2,633 |
| Revenue growth | +10.6% | -1.2% | +15.2% | -17.8% | +27.1% | +31.5% | - |
| Other income | 304 | 215 | 167 | 240 | 224 | 135 | 139 |
| Total expenses | 2,913 | 2,674 | 2,759 | 2,654 | 2,890 | 2,161 | 1,678 |
| Employee cost | 529 | 439 | 410 | 400 | 339 | 311 | 278 |
| EBITDA | 1,639 | 1,443 | 1,409 | 962 | 1,511 | 1,302 | 955 |
| EBITDA margin | +36.0% | +35.1% | +33.8% | +26.6% | +34.3% | +37.6% | +36.3% |
| Depreciation | 176 | 169 | 162 | 147 | 110 | 98.78 | 94.59 |
| Interest | 18.07 | 22.84 | 7.84 | 7.41 | 5.24 | 3.41 | 7.18 |
| Profit before tax | 1,748 | 1,466 | 1,405 | 1,048 | 1,619 | 1,335 | 993 |
| Tax | 449 | 376 | 362 | 273 | 407 | 338 | 220 |
| Net profit | 1,315 | 1,088 | 1,044 | 815 | 1,209 | 997 | 760 |
| Net profit margin | +28.9% | +26.4% | +25.0% | +22.6% | +27.5% | +28.8% | +28.9% |
| EPS (βΉ) | 78.88 | 66.14 | 63.34 | 47.11 | 73.78 | 60.95 | 49.88 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.48 | 16.48 | 16.47 | 16.47 | 16.43 | 16.36 | 15.50 |
| Reserves & surplus | 10,794 | 9,739 | 8,979 | 7,937 | 7,142 | 5,887 | 3,631 |
| Shareholders' funds (net worth) | 10,810 | 9,755 | 8,995 | 7,953 | 7,158 | 5,903 | 3,646 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 2.75 | 5.23 | 3.66 | 4.45 | 4.74 | 5.00 | 4.96 |
| Total debt | 2.75 | 5.23 | 3.66 | 4.45 | 4.74 | 5.00 | 4.96 |
| Total liabilities | 10,860 | 9,783 | 9,020 | 7,959 | 7,165 | 5,910 | 3,654 |
| Assets | |||||||
| Gross block | 2,915 | 2,798 | 2,580 | 2,295 | 2,081 | 1,431 | 1,348 |
| Net block | 1,688 | 1,745 | 1,694 | 1,571 | 1,502 | 954 | 968 |
| Capital work in progress | 138 | 42.21 | 120 | 177 | 191 | 338 | 188 |
| Investments | 3,293 | 2,790 | 2,386 | 8.16 | 163 | 0.55 | 0.00 |
| Inventories | 1,265 | 1,254 | 1,260 | 1,945 | 1,186 | 1,275 | 756 |
| Sundry debtors | 1,521 | 1,143 | 1,171 | 863 | 1,075 | 671 | 602 |
| Cash & bank balances | 3,178 | 2,433 | 1,599 | 3,767 | 3,086 | 3,005 | 1,325 |
| Loans & advances | 459 | 937 | 541 | 313 | 343 | 172 | 163 |
| Total current assets | 6,422 | 5,767 | 4,571 | 6,888 | 5,690 | 5,123 | 2,846 |
| Total current liabilities | 633 | 522 | 413 | 729 | 582 | 512 | 358 |
| Net working capital | 5,789 | 5,245 | 4,158 | 6,159 | 5,108 | 4,611 | 2,488 |
| Total assets | 10,860 | 9,783 | 9,020 | 7,959 | 7,165 | 5,910 | 3,654 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2,433 | 116 | 1,905 | 311 | 492 | 170 | 236 |
| Net cash from operating activities | 1,135 | 1,074 | 1,136 | 368 | 791 | 605 | 701 |
| Net cash from investing activities | (74.03) | 1,582 | (2,918) | 1,211 | (1,007) | (1,521) | (761) |
| Net cash from financing activities | (316) | (340) | (7.40) | 14.92 | 34.90 | 1,238 | (6.87) |
| Net change in cash | 745 | 2,316 | (1,789) | 1,594 | (181) | 322 | (66.91) |
| Closing cash | 3,178 | 2,433 | 1,599 | 3,767 | 3,086 | 3,005 | 1,325 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.6% | -1.2% | +15.2% | -17.8% | +27.1% | +31.5% | - |
| EBITDA growth | +13.6% | +2.4% | +46.4% | -36.3% | +16.0% | +36.3% | - |
| PBT growth | +19.3% | +4.3% | +34.1% | -35.3% | +21.3% | +34.5% | +44.7% |
| Net income growth | +20.9% | +4.3% | +28.0% | -32.6% | +21.3% | +31.2% | - |
| Revenue CAGR (3Y) | +8.0% | -2.2% | +6.4% | +11.2% | +29.1% | +28.8% | +21.2% |
| EBITDA CAGR (3Y) | +19.4% | -1.5% | +2.7% | +0.2% | +30.1% | +34.5% | +15.2% |
| Profitability & leverage | |||||||
| Net income margin | +28.6% | +26.5% | +25.0% | +21.5% | +27.5% | +28.8% | +29.4% |
| Return on capital employed | +17.1% | +15.8% | +16.7% | +14.0% | +24.9% | +28.0% | +30.6% |
| Return on net worth | +12.6% | +11.6% | +12.3% | +10.3% | +18.6% | +20.9% | +23.8% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.24 | 1.79 | 0.63 | 0.91 | 0.37 | 0.28 | 0.83 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.59 | 1.53 | 1.71 | 1.65 | 2.51 | 2.49 | 2.05 |
| Inventory turnover | 3.61 | 3.27 | 2.60 | 2.31 | 3.58 | 3.41 | 3.16 |
| Debtors turnover | 3.42 | 3.56 | 4.10 | 3.73 | 5.04 | 5.44 | 4.75 |
| EPS (βΉ) | 78.88 | 66.14 | 63.34 | 47.11 | 73.78 | 60.95 | 49.88 |
| Dividend per share (βΉ) | 20.00 | 18.00 | 20.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 656.11 | 592.08 | 546.13 | 482.90 | 435.68 | 360.86 | 235.32 |
Investments & Acquisitions by Gland Pharma
Gland Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cenexi.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pre-formulation and formulation services are provided in pharmaceuticals. | cenexi.com | 2004 | Nov 2022 | β’β’β’β’ |
Complete acquisition details for Gland Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Gland Pharma
6 dated milestones of Gland Pharma across 44 years, from founding to its latest funding, stage changes and deals.
Web traffic of Gland Pharma
The website of Gland Pharma (glandpharma.com) receives about 8.4K visits a month and ranks #3,685,423 among all websites worldwide, #4,728 in Biotechnology and Pharmaceuticals.
- Monthly visits8.4K
▲ 56.1% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,685,423
among all websites
- Category rank#4,728
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.7
- Average visit11 sec
- DevicesDesktop 36% Β· Mobile 64%
Websites whose visitors overlap most with Gland Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cadilapharma.com | 100% | 18.5K | #1,452,788 | View details | |
| greencrossindia.com | 62% | 1.7K | #3,821,526 | View details | |
| genixpharma.com | 62% | View details | |||
| cipla.com | 38% | 200.9K | #203,362 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Gland Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gland Pharma
Complete news archive for Gland Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gland Pharma
Gland Pharma was founded in 1978 and raised its 1st funding round 35 years after it was founded.
Gland Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Srinivas Sadu is the CEO of Gland Pharma, as recorded in our data.
Gland Pharma has 4,332 employees.
The primary company behind Gland Pharma, Gland Pharma Ltd, reported revenue of βΉ6,747 Cr for FY 2026, up 14% year on year.
The company was founded in 1978 in Hyderabad, India, and operates in the pharmaceutical sector as a manufacturer of generic injectable drugs. A portfolio of products has been established in sterile injectables, oncology, and ophthalmics, with emphasis on complex injectables and various delivery systems. Diverse injectable needs are addressed through a stable supply chain, serving global markets from its base in India.
Yes, Gland Pharma is publicly traded on NSE under the ticker symbol GLAND.
Gland Pharma has made 1 acquisition, including Cenexi.
Gland Pharma has 3 investors. Key investors include KKR, Fosun, and Gland Celsus Bio Chemicals.
The valuation of Gland Pharma is $445.93M as of Nov 2013.
Gland Pharma operates through Gland Pharma Ltd.
Yes. Gland Pharma was acquired by Fosun in July 2016.
